Companies /Healthcare

Ionis Pharmaceuticals Inc

NASDAQ: IONS Biotechnology
$28.34
▼ $0.72 (−2.48%) today
Markets open · 2:06pm ET

24/7 Wall St. View

IONS at a Glance

Valuation
Market cap
$4.8B
Profitability
Revenue (TTM)
$960.1M
Profit margin
-56.9%
EPS (TTM)
$-3.35
Price
52-week range
$27 – $87
Street target
$68.48
Earnings
Q3 2026 EPS
$-0.66
vs. $-0.93 est.
+29.4%

Headquartered in Carlsbad, CA Fiscal year ends December NASDAQ: IONS ionis.com

About Ionis Pharmaceuticals

Ionis Pharmaceuticals is a biotechnology company focused on RNA-targeted medicines, with marketed products and a pipeline in neurology, cardiometabolic disease and select areas of high patient need. It is also advancing new approaches in gene editing.

Ionis now sells three wholly owned medicines:
- **TRYNGOLZA (olezarsen):** approved for severe hypertriglyceridemia (sHTG) and familial chylomicronemia syndrome (FCS).
- **DAWNZERA (donidalorsen):** an RNA-targeted prophylactic therapy for hereditary angioedema.
- **ZANVASTRO (zilganersen):** for Alexander disease, Ionis' first independent neurology launch.

The company also earns royalties and collaboration revenue from partnered medicines, including:
- Biogen's SPINRAZA (spinal muscular atrophy) and QALSODY.
- AstraZeneca's WAINUA/WAINZUA (ATTRv-PN).
- GSK's HIBSAGO (bepirovirsen) for chronic hepatitis B.

Its R&D revenue comes from multiple partnerships, including Ono Pharmaceutical (sapablursen) and Recordati (ex-U.S. ZANVASTRO). Late-stage pipeline assets include:
- Obudanersen (Angelman syndrome).
- Sefaxersen (IgA nephropathy).
- Ulefnersen (FUS-ALS).
- Pelacarsen (Lp(a)-CVD).
- Salanersen (SMA).
- Sapablursen (polycythemia vera).
- ION775 (sHTG siRNA).
- Diranersen (Alzheimer's disease). Updated

Revenue by Segment · Q3 2026
  1. Collaborative Agreement Revenue42%
  2. SPINRAZA Royalties28%
  3. DAWNZERA15%
  4. TRYNGOLZA4%
  5. WAINUA Royalties3%
  6. Other Commercial Revenue3%
  7. Other Royalties2%
  8. WAINUA Joint Development Revenue2%
  9. ZANVASTRO1%

Latest Activity

Earnings on deck — Nov 9–13
601 companies248 before open353 after close

601 companies report next week, and Monday alone front-loads the power trade: Constellation Energy, NRG and Fervo Energy all deliver before the open, alongside KKR, Barrick Mining and monday.com. Data center electricity demand gets its clearest read of the quarter.

  • CEGConstellation Energy CorporationMon Nov 9Before open
  • MNDYmonday.com Ltd.Mon Nov 9Before open
  • NRGNRG Energy, Inc.Mon Nov 9Before open
  • SBETSharplink, Inc.Mon Nov 9Before open
  • VRTSVirtus Investment Partners, Inc.Mon Nov 9Before open
  • BBarrick Mining CorporationMon Nov 9Before open
  • CEVACeva, Inc.Mon Nov 9Before open
  • CGENCompugen Ltd.Mon Nov 9Before open
  • IONSIonis Pharmaceuticals, Inc.Mon Nov 9Before open
  • UNITUniti Group Inc.Mon Nov 9Before open
  • FRVOFervo Energy CompanyMon Nov 9Before open
  • HRTXHeron Therapeutics, Inc.Mon Nov 9Before open
  • KGSKodiak Gas Services, Inc. Mon Nov 9Before open
  • KKRKKR & Co. Inc.Mon Nov 9Before open
  • KSPIJoint Stock Company Kaspi.kzMon Nov 9Before open

IONS Coverage

Frequently Asked Questions

What does Ionis Pharmaceuticals do?

Ionis Pharmaceuticals is a biotechnology company focused on RNA-targeted medicines, with marketed products and a pipeline in neurology, cardiometabolic disease and select areas of high patient need. It is also advancing new approaches in gene editing.

What is the IONS stock price target?

The Wall Street consensus 12-month price target for IONS is $68.48. IONS price prediction →